192 related articles for article (PubMed ID: 35453576)
1. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.
Lin YT; Yu CL; Tu YK; Chi CC
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453576
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
3. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
Dao DD; Pixley JN; Akkurt ZM; Feldman SR
Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
5. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
6. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
8. Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient.
Vasani RJ
Indian J Dermatol; 2015; 60(2):165-9. PubMed ID: 25814705
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
10. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
[TBL] [Abstract][Full Text] [Related]
11. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
12. Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.
Ebrahimi-Fakhari D; Müller CSL; Meyer S; Flotats-Bastardas M; Vogt T; Pföhler C
Dermatol Ther (Heidelb); 2017 Mar; 7(1):175-179. PubMed ID: 28181194
[TBL] [Abstract][Full Text] [Related]
13. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
14. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
15. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
16. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
18. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial.
Aitken P; Stanescu I; Boddington L; Mahon C; Fogarasi A; Liao YH; Ivars M; Moreno-Artero E; Trauner D; DeRoos ST; Jancic J; Nikolic M; Balážová P; Price HN; Hadzsiev K; Riney K; Stapleton S; Tollefson MM; Bauer D; Pinková B; Atkinson H
Br J Dermatol; 2023 Oct; 189(5):520-530. PubMed ID: 37463422
[TBL] [Abstract][Full Text] [Related]
19. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
20. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
